Groundbreaking Results for the IRD Community

According to Technology Networks, results from a phase 1/2 clinical trial called BRILLIANCE show that an experimental CRISPR gene editing therapy is safe and led to measurable vision improvements in trial participants. Reported in The New England Journal of Medicine and led by researchers including Dr. Eric Pierce of Mass Eye and Ear, the study evaluated the in vivo gene editing treatment known as EDIT-101. This milestone development offers a significant proof of concept for the inherited retinal disease (IRD) community, particularly for individuals affected by conditions where traditional gene augmentation is not an option.

Key Findings from the BRILLIANCE Trial

The clinical trial enrolled 14 participants—including 12 adults and two children ranging from ages 10 to 63—who were born with Leber Congenital Amaurosis (LCA) caused by mutations in the CEP290 gene. Participants received a single injection of the EDIT-101 therapy in one eye.

According to the source material:
- 11 out of the 14 treated participants (approximately 79%) demonstrated measurable improvements in at least one key vision-related outcome.
- Six participants experienced improvements in two or more vision outcomes.
- Four participants showed clinically meaningful improvements in best-corrected visual acuity (BCVA).
- Six participants experienced meaningful improvements in cone-mediated vision based on dark-adapted full-field stimulus testing (FST).
- Regarding safety, researchers reported no serious treatment-related adverse events and no dose-limiting toxicities.

What This Means for Patients and Families

For families navigating life with rare inherited blindness, these findings represent an encouraging step forward. Patients shared meaningful real-world impacts, such as improved ability to locate misplaced items or recognize illuminated indicators on household appliances. Because LCA type 10 currently has no FDA-approved treatments, exploring alternative therapeutic avenues like CRISPR genome editing provides new hope for conditions previously deemed untreatable.

Moving Forward

The research team indicated that the findings support continued research and clinical trials of CRISPR-based therapies for inherited retinal disorders. Investigators plan to use the data and learnings from the BRILLIANCE trial to guide the ongoing development of innovative genetic medicines for the IRD community.